ICIs, including but not limited to anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), anti-programmed death-1 (PD-1) and anti-programmed death-1 ligand 1 (PD-L1), have demonstrated significant efficacy in the treatment of various cancers. This evidence concerns the gene CD274 and cancer.